Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Aligos Therapeutics Inc
ALGS | US
6.40
USD0.27
4.40%
ALGS | US
Loading StockChartView...
About Aligos Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
6.40
Open
6.22
High
6.57
Low
6.00
Aligos Therapeutics Inc. a clinical-stage biopharmaceutical company focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558 which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184 a capsid assembly modulator which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009 a small molecule THR-ß agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition it develops siRNA drug candidate ALG-125755 which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics Inc. has entered into license and collaboration agreements with Luxna Biotech Co. Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research licensing and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover research optimize and develop oligonucleotides directed against a NASH as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co. Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco California.
View LessALGS | US
Risk
96.8
Sharpe
0.16
Luna's Score
39/100
Recommendation
Sell
Luna says (ALGS | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
112.1%1 month
96.8%3 months
80.4%6 months
86.4%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.34
Debt to equity
0.15
Debt to assets
0.09
Ent. to EBITDA
0.57
Ent. to rev.
121.03
PEG
-
Other Fundamentals
EBITDA
-91.56M
MarketCap
20.46M
MarketCap(USD)
20.46M
Div. yield
-
Op. margin
-2.49K
Erngs. growth
-
Rev. growth
-84.60
Ret. on equity
-110.67
Short ratio
0.90
Short perc.
6.47
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
3.00
Range1M
3.00
Range3M
3.02
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.41
Price X volume
1.02M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.57 | 0.53 | Par |
| Ent. to Revenue | 121.03 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.34 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 80.42 | 72.80 | Par |
| Debt to Equity | 0.15 | -1.23 | Expensive |
| Debt to Assets | 0.09 | 0.25 | Cheaper |
| Market Cap | 20.46M | 3.66B | Emerging |
